Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

LIVN

LivaNova PLC

Last Close
78.97
Oct 30 • 3:59 PM ET Dollar change-2.28 Percentage change(-2.81%)
Aftermarket Close
78.97
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Medical Devices United Kingdom Mid NASD
Peers: MDT NPCE INSP BSX ABT TMDX HAE ECOR ITGR STIM
 | Held by: IJH AVUV IWM VXF DFAT XMMO DFAS XMHQ IWN MDY
Scroll to Statements
Index
RUT
Market Cap
4.35B
Enterprise Value
4.19B
Income
188.54M
Sales
1.47B
Book/sh
24.07
Cash/sh
9.38
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
3300
IPO
Feb 11, 1993
P/E
23.43
Forward P/E
16.86
PEG
1.63
P/S
2.96
P/B
3.28
P/C
8.42
P/FCF
29.34
EV/EBITDA
14.71
EV/Sales
2.84
Quick Ratio
1.21
Current Ratio
1.45
Debt/Eq
0.27
LT Debt/Eq
0.26
Option/Short
Yes / Yes
EPS (ttm)
3.37
EPS next Y
4.68
EPS next Q
1.06
EPS this Y
11.71%
EPS next Y
7.51%
EPS next 5Y
10.32%
EPS past 3/5Y
-40.20% 9.06%
Sales past 3/5Y
10.75% 8.24%
EPS Y/Y TTM
188.56%
Sales Y/Y TTM
12.39%
EPS Q/Q
288.60%
Sales Q/Q
10.80%
Earnings
Nov 04 BMO
EPS/Sales Surpr.
15.12% 2.65%
Insider Own
0.41%
Insider Trans
-5.49%
Inst Own
110.84%
Inst Trans
-0.24%
ROA
7.33%
ROE
15.40%
ROIC
11.32%
Gross Margin
68.24%
Oper. Margin
15.01%
Profit Margin
12.81%
SMA20
0.87%
SMA50
0.61%
SMA200
8.33%
Trades
Shs Outstand
55.05M
Shs Float
54.87M
Short Float
11.30%
Short Ratio
9.61
Short Interest
6.20M
52W High
85.76 -7.92%
52W Low
48.82 61.76%
Volatility
2.71% 2.80%
ATR (14)
2.25
RSI (14)
50.81
Beta
0.92
Rel Volume
0.89
Avg Volume
644.85K
Volume
575,615
Perf Week
-2.39%
Perf Month
5.72%
Perf Quarter
-4.23%
Perf Half Y
29.46%
Perf YTD
28.34%
Perf Year
49.59%
Perf 3Y
64.83%
Perf 5Y
2.93%
Perf 10Y
39.50%
Recom
1.67
Target Price
92.10
Prev Close
81.25
Price
78.97
Change %
-2.81%
Consensus
Buy
Avg. Price Target
$92.10
Implied Upside
+16.6%
Analysts10incl. previous ratings
Rating Distribution7 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 07, 2026Initiated
BCS logoBBarclays
Overweight$105+33.0%
Dec 19, 2025Initiated
KEY logoKKeyBanc Capital Markets
Overweight$81+2.6%
Oct 01, 2025Downgrade
GS logoGGoldman
Buy → Neutral$55-30.4%
May 20, 2025Upgrade
WWolfe Research
Peer Perform → Outperform$60-24.0%
Feb 26, 2025Downgrade
WWolfe Research
Outperform → Peer Perform
Oct 04, 2024Initiated
GS logoGGoldman
Buy$65-17.7%
Sep 17, 2024Upgrade
RRobert W. Baird
Neutral → Outperform$55 → $66-16.4%
Mar 20, 2024Reiterated
NNeedham
Buy
Feb 20, 2024Upgrade
MFG logoMMizuho
Neutral → Buy$60 → $70-11.4%
Sep 06, 2023Initiated
HSBC logoHHSBC Securities
Hold$52-34.2%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bianchi FrancescoDirectorSep 10 '26Sale78.013,500273,0324,434Sep 14 04:23 PM
Bianchi FrancescoOfficerSep 10 '26Proposed Sale78.013,500273,032Sep 10 04:27 PM
Story BrookeDirectorSep 04 '26Sale81.422,300187,2707,488Sep 08 05:01 PM
Story BrookeOfficerSep 04 '26Proposed Sale81.422,300187,270Sep 04 04:15 PM
Poletti FrancoOfficerSep 02 '26Proposed Sale82.0910,755882,888Sep 02 04:24 PM
Bianchi FrancescoDirectorAug 31 '26Sale79.721,650131,5387,934Sep 02 04:19 PM
Bianchi FrancescoOfficerAug 31 '26Proposed Sale79.721,650131,538Aug 31 04:12 PM
Tezel AhmetChief Innovation OfficerAug 11 '26Option Exercise52.6812,692668,61518,782Aug 13 04:04 PM
Tezel AhmetChief Innovation OfficerAug 11 '26Sale77.742,675207,9426,090Aug 13 04:04 PM
Tezel AhmetOfficerAug 11 '26Proposed Sale78.482,675209,942Aug 11 04:12 PM
WILVER PETER MDirectorJun 15 '26Option Exercise0.004,042010,780Jun 17 04:09 PM
SCHERMERHORN TODD CDirectorJun 15 '26Option Exercise0.004,042013,105Jun 17 04:09 PM
Bianchi FrancescoDirectorJun 15 '26Option Exercise0.004,042011,270Jun 17 04:09 PM
Bianchi FrancescoDirectorJun 15 '26Sale80.191,20096,2289,584Jun 17 04:09 PM
PODLOGAR SUSAN MDirectorJun 15 '26Option Exercise0.004,04206,128Jun 17 04:09 PM
Barry James ChristopherDirectorJun 15 '26Option Exercise0.004,04208,404Jun 17 04:09 PM
Tezel AhmetChief Innovation OfficerJun 15 '26Option Exercise0.002,96507,122Jun 17 04:09 PM
KOZY WILLIAM ADirectorJun 15 '26Option Exercise0.005,681038,248Jun 17 04:09 PM
Enxing Seng StacyDirectorJun 15 '26Option Exercise0.004,042015,793Jun 17 04:08 PM
Story BrookeDirectorJun 15 '26Option Exercise0.004,042010,274Jun 17 04:08 PM
Zurbay DonaldDirectorJun 15 '26Option Exercise0.002,56002,560Jun 17 04:08 PM
Bianchi FrancescoOfficerJun 15 '26Proposed Sale80.191,20096,228Jun 15 04:56 PM
Bianchi FrancescoDirectorMay 26 '26Sale75.751,800136,3507,228May 27 04:51 PM
Bianchi FrancescoOfficerMay 26 '26Proposed Sale75.751,800136,350May 26 04:37 PM
Tezel AhmetChief Innovation OfficerMar 30 '26Option Exercise0.003,40805,343Apr 01 05:20 PM
Poletti FrancoPresident, CardiopulmonaryMar 30 '26Option Exercise0.003,184012,125Apr 01 05:20 PM
Shvartsburg AlexChief Financial OfficerMar 30 '26Option Exercise0.0030,835057,515Apr 01 05:20 PM
Makatsaria VladimirChief Executive OfficerMar 30 '26Option Exercise0.0021,042025,326Apr 01 05:20 PM
Bolton StephaniePresident, Global EpilepsyMar 30 '26Option Exercise0.0017,815030,566Apr 01 05:20 PM
Kozmina NataliaChief Human Resources OfficerMar 30 '26Option Exercise0.006,38906,389Apr 01 05:20 PM
Poletti FrancoPresident, CardiopulmonaryMar 11 '26Option Exercise57.602,140123,26410,990Mar 13 05:25 PM
Poletti FrancoPresident, CardiopulmonaryDec 15 '25Option Exercise0.0096709,266Dec 17 04:06 PM
PODLOGAR SUSAN MDirectorDec 15 '25Option Exercise0.002,35502,355Dec 17 04:06 PM
Hutchinson Michael DamonSVP, CLO and Company SecretaryDec 15 '25Option Exercise0.002,25407,920Dec 17 04:06 PM
Story BrookeDirectorNov 18 '25Sale53.9425013,4856,232Nov 19 03:57 PM
Story BrookeDirectorNov 18 '25Proposed Sale53.9425013,485Nov 18 04:51 PM
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
CEO & DirectorMr. Vladimir A. Makatsaria
Chief Financial OfficerMr. Alex Shvartsburg C.M.A.
Chief Human Resources OfficerMs. Natalia Sergeyevna Kozmina
Chief Innovation OfficerMr. Ahmet Tezel Ph.D.
VP & Chief Accounting OfficerMs. Lindsey Little
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)